# US 6,727,239 B1 · Derivatives of 2-aminopyridines, their use as medicaments and pharmaceutical compositions containing them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,239 B1
- Document ID: US6727239B1
- Status: Granted
- Kind: B1
- Application number: 10/405,828
- Filed: 2003-04-02
- Granted: 2004-04-27
- Earliest claimed: 1998-07-08
- Assignees: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
- Inventors: Pierre-Etienne Chabrier de Lassauniere; Serge Auvin; Jerry Harnett; Dominique Pons; Gérard Ulibarri; Dennis Bigg
- Web page: https://patentgrep.com/patent/US6727239B1

## CPC

- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 213/73: Unsubstituted amino or imino radicals
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- A01K 2267/03: Animal model, e.g. for test or diseases
- A01K 2267/0325: Animal model for autoimmune diseases
- A01K 2267/0368: Animal model for inflammation
- A01K 2267/0381: Animal model for diseases of the hematopoietic system
- A61K 2039/505: {comprising antibodies}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A compound of the formula wherein the substituents are defined as in the specification and their pharmaceutically acceptable salts having NOS and ROS activity.

## Claims

### Claim 1

A compound of the formula
wherein A represents
R8 is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, —CO—R9 radical, arylalkyl unsubstituted or substituted with at least one alkyl or alkoxy of 1 to 6 carbon atoms, R9 is alkyl of 1 to 6 carbon atoms, X is selected from the group consisting of —(CH2)m—Q—, —(CH2)m—CH═CH—Q—, —(CH2)m—C(═W)—Q—, —(CH2)m—NR11—C(═W)—Q—, —(CH2)m—NR11—C(═W)—O—Q—, —(CH2)m—NR11—C(═W)—NR12—Q—, —(CH2)m—NH—Z—NH—C(═W)—, —(CH2)m—N═C(R16)—NR12—, —(CH2)m—CH═CH—C(═W)—Q and alkenyl radical of up to 6 carbon atoms, Q is selected from the group consisting of a bond, piperazine, homopiperazine, piperidine, pyrrolidine and azetidine, all unsubstituted or substituted with at least one alkyl of 1 to 6 carbon atoms, W is selected from the group consisting of oxygen, sulfur and —NH—, Z is phenylene unsubstituted or substituted with at least one halogen, m is an integer from 0 to 6, Y is selected from the group consisting of a) alkyl, alkenyl and alkynyl of up to 10 carbon atoms, each unsubstituted or substituted with —NR13R14, and b) —(CH2)n—O—(CH2)p—, —(CH2)n—S—(CH2)p— and —(CH2)n—NR13—(CH2)p—, n and p are individually integers from 0 to 6, R10 is selected from the group consisting of hydrogen, —OH, —CN, —NO2, —SR15 and alkyl and alkoxy of 1 to 6 carbon atoms, R11, R12, R13, R14 and R15 are individually hydrogen atom or alkyl of 1 to 6 carbon atoms, R16 is selected from the group consisting of hydrogen atom and alkyl and thioalkyl of 1 to 6 carbon atoms with the proviso (1) that —X—Y— together are not a member of the group consisting of a single bond, alkylene, —O—, —S—, —NH— and —NH—CO—NH-alkylene, (2) when A is phenylene, —X—Y— together are not —NH—CO—NH— and (3) when A is 3,4,5-trialkoxyphenylene, —X—Y— together are not —CO—NH—CH2—, or its salts with non-toxic, pharmaceutically acceptable acids or bases.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Y is —(CH2)n—NR13—(CH2)p—, R13 is hydrogen or alkyl of 1 to 6 carbon atoms and n and p are individually integers from 0 to 6.

### Claim 3 (depends on 1)

The compound of claim 1, wherein A is
and R8 is hydrogen.

### Claim 4 (depends on 2)

The compound of claim 2, wherein X is —NH—CO— or —CO—Q—, Q is piperazine unsubstituted or substituted with one or two methyl, Y is —(CH2)n—NR13—(CH2)p—, R13 is hydrogen or alkyl of 1 to 6 carbon atoms, n and p are individually integers from 0 to 6, or Y is selected from the group consisting of alkyl, alkenyl and alkynyl of up to 10 carbon atoms and R10 is hydrogen atom or methyl.

### Claim 5 (depends on 1)

The compound of claim 1 which is selected from the group consisting of:
-1-[4-(2-amino-5-pyridinyl)-3-butynyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride;
-1-[4-(2-amino-5-pyridinyl)butyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride;
-1-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride;
-1-[4-(2-amino-6-pyridinyl)-3-butynyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride; and
-N-[4-(6-amino-4-methyl-2-pyridinyl)butyl]-6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxamide fumarate.

### Claim 6

A method of inhibiting lipidic peroxidation in a mammal in need thereof by administering to said mammal a therapeutically effective amount of a compound of general formula
in which A is
R8 is selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms, —CO—R9, arylalkyl unsubstituted or substituted with at least one alkyl or alkoxy of 1 to 6 carbon atoms, R9 is alkyl of 1 to 6 carbon atoms, X is selected from the group consisting of —(CH2)m—Q—, —(CH2)m—CH═CH—Q—, —(CH2)m—C(═W)—Q—, —(CH2)m—NR11—C(═W)—Q—, —(CH2)m—NR11—C(═W)—O—Q—, —(CH2)m—NR11—C(═W)—NR12—Q—, —(CH2)m—NH—Z—NH—C(═W)—, —(CH2)m—N═C(R16)—NR12—, —(CH2)m—CH═CH—C(═W)—Q and alkenyl of up to 6 carbon atoms, Q is selected from the group consisting of a bond and piperazine, homopiperazine, piperidine, pyrrolidine and azetidine unsubstituted or substituted with at east one alkyl of 1 to 6 carbon atoms, W is selected from the group consisting of oxygen, sulfur and NH, Z is phenylene unsubstituted or substituted with at least one halogen, m is an integer from 0 to 6, Y is selected from the group consisting of alkyl, alkenyl and alkynyl chain, each of up to 10 carbon atoms and unsubstituted or substituted by —NR13R14, or Y is selected from the group consisting of (CH2)n—O—(CH2)p—, —(CH2)n—S—(CH2)p— and —(CH2)n—NR13—(CH2)p—, n and p are individually integers from 0 to 6, R10 is selected from the group consisting of hydrogen, —OH, —CN, —NO2, —SR15 and alkyl or alkoxy of 1 to 6 carbon atoms, R11, R12, R13, R14 and R15 are individually hydrogen or alkyl of 1 to 6 carbon atoms, R16 is selected from the group consisting of hydrogen and alkyl or thioalkyl of 1 to 6 carbon atoms, with the proviso that (1) —X—Y— are not selected from the group consisting of a single bond, alkylene, —O—, —S—, —NH— and —NH—CO—NH-alkylene and (2) when A is phenyl, —X—Y— together are not —NH—CO—NH—, with the exception of N-(2-amino-6-methyl-3-pyridylmethyl)-3,4,5-trimethoxybenzamide, N-(2-amino-3-pyridylmethyl)-3,4,5-trimethoxybenzamide and N-(2-amino-6-methyl-3-pyridylmethyl)-3,4,5-triethoxybenzamide, or its salt with a non-toxic, pharmaceutically acceptable acid or base.

### Claim 7 (depends on 6)

A method of effecting neurodegenerative diseases in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of general formula (I)′ as defined in claim 6, or a salt of this compound with a non-toxic, pharmaceutically acceptable acid or base.

### Claim 8 (depends on 7)

The method of claim 7, wherein the neurodegenerative diseases are selected from the group consisting of Alzheimer's disease, Huntington's chorea, Parkinson's disease, Creutzfeld Jacob disease and prio diseases and amyotrophic lateral sclerosis.

### Claim 9 (depends on 8)

The method of claim 8, wherein the neurodegenerative disease is Parkinson's disease.

### Claim 10 (depends on 8)

The method of claim 8, wherein the compound administered is selected from the group consisting of:
-1-[4-(2-amino-5-pyridinyl)-3-butynyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride;
-1-[4-(2-amino-5-pyridinyl)butyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride;
-1-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride;
-1-[4-(2-amino-6-pyridinyl)-3-butynyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride; and
-N-[4-(6-amino-4-methyl-2-pyridinyl)butyl]-6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxamide fumarate.

### Claim 11 (depends on 5)

A method for treating cardio-vascular and cerebro-vascular disorders in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of a compound of general formula (I)′ as defined in claim 5, or a salt of this compound with a non-toxic, pharmaceutically acceptable acid or base.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cardio-vascular and cerebro-vascular disorders are ischemic or hemorragic cardiac infarctions.

### Claim 13 (depends on 1)

The method of claim 1, wherein the compound administered is selected from the group consisting of:
-1-[4-(2-amino-5-pyridinyl)-3-butynyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride;
-1-[4-(2-amino-5-pyridinyl)butyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride;
-1-[2-(6-amino-4-methyl-2-pyridinyl)ethyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride;
-1-[4-(2-amino-6-pyridinyl)-3-butynyl]-4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-[1]-benzopyran-2-yl)carbonyl]-piperazine hydrochloride; and
-N-[4-(6-amino-4-methyl-2-pyridinyl)butyl]-6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxamide fumarate.
